Specialty Pharmacy

Roche today announced that the FDA has accepted the company's Biologics License Application (BLA) for obinutuzumab (GA101) and granted Priority Review for GA101 in the treatment of chronic lymphocytic leukemia (CLL).

BioPlus was selected as a specialty pharmacy supplier for the new Tarceva network.

Research presented on June 25, 2013, at the Drug Information Association (DIA) 2013 49th Annual Meeting could trigger a paradigm shift in clinical trial patient recruitment and could change the way pharmacists engage with patients as new drugs make their way through the FDA approval process.

Diplomat Specialty Pharmacy, the country's largest independent specialty pharmacy servicing the needs of patients and physicians nationwide, is pleased to announce the company's compounding pharmacy has been accredited by the Pharmacy Compounding Accreditation Board (PCAB).

Pharmacy accreditation is starting to gain some recognition, noted Quintin Jessee, RPh, DPh, D2 Pharma Consulting in this video shot at the 2013 Armada Specialty Pharmacy Summit in Las Vegas, Nevada.

The Drug Information Association's (DIA) 49th Annual Meeting will cover information about rare disease, recruiting for clinical trials, and updates from the Center for Biologics Evaluation Research.

The updates issued by the FDA address the rules and language from the Orphan Drug Act governing orphan-drug designation and orphan-drug exclusivity.

Adam J. Fein of Drug Channels explains the reasons drug manufacturers choose limited distribution channels.

Specialty Pharmacy Times sat down to talk with Dr. Eric Sredzinski about the controversial topic of pricing for oncology medications, as well as common patient reimbursement hurdles and Avella's technologically savvy efforts to break down patient adherence barriers.

Avella Specialty Pharmacy today announced it has been identified as one of a select group of specialty pharmacies to supply Tarceva (erlotinib).

Patient engagement, financial backing, and personalized medicine-3 of the most pressing issues in drug development and regulatory affairs-will be discussed at length at the DIA 2013 49th Annual Meeting, June 23-27 in Boston.

The court's decision makes it more likely that generic versions of medications will be made available before their patents expire and will likely lead to reduced drug costs for consumers.

New therapies advance the treatment of this hematologic cancer.

Michael Einodshofer, director, utilization management, Walgreens, describes how contractual methodologies and cost differences across various sites of service can influence how a specialty drug is reimbursed under the medical benefit.

Consumer Watchdog's latest lawsuit questions the legality of another mandatory mail-order program for specialty pharmaceuticals.

The Supreme Court today ruled that because DNA is a "product of nature," it cannot be protected by a patent-but complementary DNA made synthetically in a lab would be eligible for patent protection.

The FDA today approved denosumab (Xgeva injection, for subcutaneous use) for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.

A study published online in JAMA Psychiatry found that hospitalization for an infection or an autoimmune disease increased the risk of a subsequent mood disorder diagnosis.

At the Association for Health Insurance Plan's (AHIP) conference this Thursday, medical directors from Cardinal Health Specialty Solutions and Aetna will provide expert insight into how collaboration between payers and physicians can directly lead to better cancer care that is more effective and costs less.

CVS Caremark announced today that it has been awarded Specialty Pharmacy accreditation from URAC, a Washington, DC-based health care accrediting organization that establishes quality standards for the health care industry.

Debbie Stern, RPh, president of Rxperts, explains why a high entry cost for a specialty drug may dissuade a patient from filling and staying adherent to his or her prescription.

The new process takes into account the efficacy, risk, cost, and societal benefit of a given specialty drug in determining whether it should be added to the hospital's formulary.

The Biotechnology Industry Organization (BIO) and Oregon Bioscience Association (Oregon Bio) commend Oregon Governor John Kitzhaber for signing legislation designed to address the regulatory issues related to the interchangeability of biological medicines.

Adam Fein describes the way in which the sequester will affect physician reimbursement for specialty drugs.

Illinois is now the 13th state to avoid enacting legislation that would slow patient access to biosimilars, which are new, affordable versions of costly brand biologic medicines that treat cancer, immune disorders and other complex diseases.

Prime Therapeutics, a leading pharmacy benefit manager, announced today that its specialty pharmacy, Prime Therapeutics Specialty Pharmacy, has received full accreditation from URAC.

The last day of ASCO is today! Check out these social media updates to see what has been popular at the meeting.